During the screening visit, you must be at least 12 years old and have been diagnosed with Hidradenitis Suppurativa (HS) for at least 6 months

Your condition must be mild to moderate, with at least 4 affected areas in at least 2 different body regions (such as underarms, groin folds, or under-breast areas)

You must not have any draining tunnels

You will receive either ruxolitinib 1.5% cream or a cream without active ingredients (vehicle cream)

The cream needs to be applied to affected areas twice daily

This double-blind period lasts for 16 weeks, meaning neither you nor the study staff will know which cream you are using

During the study, you cannot use any antibiotics for HS treatment

You must avoid using antiseptic products on affected areas, including special washes containing chlorhexidine, iodine, bleach, or benzoyl peroxide

Regular soap and water are permitted for cleaning

At week 16, your condition will be evaluated to measure the treatment’s effectiveness

The main goal is to achieve at least 75% reduction in the number of affected areas

Your skin pain levels will be assessed if you had significant pain at the start of the study

After the initial 16 weeks, the study continues with an open-label extension period

The same treatment restrictions regarding antibiotics and antiseptics continue through week 20 of this extension period